An evidence-based review of a lentinula edodes mushroom extract as complementary therapy in the surgical oncology patient

Journal of Parenteral and Enteral Nutrition

Volumn 35, Issue 4, 2011, Pages 449-458

  Shah, Shinil K ^a   Walker, Peter A ^a   Moore Olufemi, Stacey D ^a,b   Sundaresan, Alamelu ^a,c   Kulkarni, Anil D ^a   Andrassy, Richard J ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

AHCC compound; Dietary supplement; Enteral nutrition; Immunonutrition; Lentinula edodes; Oncology; Review

Indexed keywords

ACTIVE HEXOSE CORRELATED COMPOUND; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOSTIMULATING AGENT; LENTINULA EDODES EXTRACT; MERCAPTOPURINE; METHOTREXATE; PHYTOHEMAGGLUTININ; TEGAFUR; UNCLASSIFIED DRUG; URACIL;

ALTERNATIVE MEDICINE; BIBLIOGRAPHIC DATABASE; BLOATING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DIARRHEA; FATIGUE; HEADACHE; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INJURY; LIVER CELL CARCINOMA; MUSCLE CRAMP; NAUSEA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SURGICAL PATIENT; TUMOR IMMUNITY; VIRUS INFECTION; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL PRODUCTS; CHINA; CISPLATIN; CYTARABINE; DEXAMETHASONE; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSION; JAPAN; NEOPLASMS; POLYSACCHARIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHIITAKE MUSHROOMS; TEGAFUR; UNITED STATES; URACIL; VIRUS DISEASES;

BASIDIOMYCOTA; LENTINULA EDODES;

EID: 80051863601     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607110380684     Document Type: Review

References (38)

1. Ritz BW, Nogusa S, Ackerman EA, Gardner EM Supplementation with active hexose correlated compound increases the innate immune response of young mice to primary influenza infection. J Nutr. 2006;136:2868-2873. (Pubitemid 44771788)
2. Ritz BW. Supplementation with active hexose correlated compound increases survival following infectious challenge in mice. Nutr Rev. 2008;66:526-531.
3. Miura T, Kitadate K, Nishioka H, Wakame K. Basic and clinical studies on active hexose correlated compound. In: Bagchi D, Lau FC, Ghosh DK, eds. Biotechnology in Functional Foods and Nutraceuticals. New York, NY: CRC Press; 2010:51-60.
4. Daddaoua A, Martinez-Plata E, Lopez-Posadas R, et al. Active hexose correlated compound acts as a prebiotic and is antiinflammatory in rats with hapten-induced colitis. J Nutr. 2007;137:1222-1228. (Pubitemid 46701915)
5. Mach CM, Fugii H, Wakame K, Smith J. Evaluation of active hex-ose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents. J Soc Integr Oncol. 2008;6:105-109.
6. Spierings EL, Fujii H, Sun B, Walshe T. A phase I study of the safety of the nutritional supplements, active hexose correlated compound, AHCC, in healthy volunteers. J Nutr Sci Vitaminol (Tokyo). 2007;53:536-539. (Pubitemid 351154876)
7. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 2000;5:4-27. (Pubitemid 30132069)
8. Matsushita K, Kuramitsu Y, Ohiro Y, et al. Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. Anticancer Drugs. 1998;9:343-350. (Pubitemid 28241824)
9. Amino Up Chemical Co, Ltd. AHCC. 2009. http://www.aminoup. co.jp/e/ahcc.html. Accessed June 5, 2010.
10. Sun B, Wakame K, Sato E, et al. The effect of active hexose correlated compound in modulating cytosine arabinoside-induced hair loss, and 6-mercaptopurine- and methotrexate-induced liver injury in rodents. Cancer Epidemiol. 2009;33:293-299.
11. Hirose A, Sato E, Fujii H, et al. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemothera-peutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol. 2007;222:152-158. (Pubitemid 47094864)
12. Gao Y, Zhang D, Sun B, et al. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immunother. 2006;55:1258-1266. (Pubitemid 43996648)
13. Ghoneum M, Wimbley M, Salem F, Mcklain A, Attallah N, Gill G. Immunomodulatory and anticancer effects of active hemicellulose compound (AHCC). Int J Immunother. 1995;11:23-28.
14. Matsui Y, Uhara J, Satoi S, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. 2002;37:78-86. (Pubitemid 34713058)
15. Cowawintaweewat S, Manoromana S, Sriplung H, et al. Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pac J Allergy Immunol. 2006;24:33-45. (Pubitemid 44044084)
16. Turner J, Chaudhary U. Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer. Anticancer Drugs. 2009;20: 215-216.
17. Uno K, Kosuna K, Sun B, et al. Active hexose correlated compound (AHCC) improves immunological parameters and performance status of patients with solid tumors. Biotherapy. (Japan) 2000;14:303-309. (Pubitemid 30241916)
18. Won JS. The hematoimmunologic effect of AHCC for Korean patients with various cancers. Biotherapy. (Japan) 2002;16:560-564. (Pubitemid 36014006)
19. Burikhanov RB, Wakame K, Igarashi Y, Wang S, Matsuzaki S. Suppressive effect of active hexose correlated compound (AHCC) on thymic apoptosis induced by dexamethasone in the rat. Endocr Regul. 2000;34:181-188.
20. Nogusa S, Gerbino J, Ritz BW. Low-dose supplementation with active hexose correlated compound improves the immune response to acute influenza infection in C57BL/6 mice. Nutr Res. 2009;29:139-143.
21. Wang S, Welte T, Fang H, et al. Oral administration of active hex-ose correlated compound enhances host resistance to West Nile encephalitis in mice. J Nutr. 2009;139:598-602.
22. Aviles H, O'Donnell P, Orshal J, et al. Active hexose correlated compound activates immune function to decrease bacterial load in a murine model of intramuscular infection. Am J Surg. 2008;195: 537-545. (Pubitemid 351417481)
23. Aviles H, O'Donnell P, Sun B, Sonnenfeld G. Active hexose correlated compound (AHCC) enhances resistance to infection in a mouse model of surgical wound infection. Surg Infect (Larchmt). 2006;7:527-535. (Pubitemid 46348303)
24. Ishibashi H, Ikeda T, Tansho S, et al. Prophylactic efficacy of a basidiomycetes preparation AHCC against lethal opportunistic infections in mice [in Japanese]. Yakugaku Zasshi. 2000;120: 715-719. (Pubitemid 30662917)
25. Ikeda T, Ishibashi H, Fujisaki R, et al. Prophylactic efficacy of a basidiomycetes preparation AHCC against lethal Candida albicans infection in experimental granulocytopenic mice [in Japanese]. Nippon Ishinkin Gakkai Zasshi. 2003;44:127-131. (Pubitemid 36604571)
26. Aviles H, Belay T, Fountain K, et al. Active hexose correlated compound enhances resistance to Klebsiella pneumoniae infection in mice in the hindlimb-unloading model of spaceflight conditions. J Appl Physiol. 2003;95:491-496. (Pubitemid 36944268)
27. Aviles H, Belay T, Vance M, et al. Active hexose correlated compound enhances the immune function of mice in the hindlimb-unloading model of spaceflight conditions. J Appl Physiol. 2004;97:1437-1444. (Pubitemid 39299363)
28. Terakawa N, Matsui Y, Satoi S, et al. Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial. Nutr Cancer. 2008;60: 643-651.
29. Matsui K, Kawaguchi Y, Ozaki T, et al. Effect of active hexose correlated compound on the production of nitric oxide in hepatocytes. JPEN J Parenter Enteral Nutr. 2007;31:373-381.
30. Sun B, Wakame K, Mukoda T, Toyoshima A, Kanazawa T, Kosuna K. Preventive effects of AHCC on carbon tetrachloride induced liver injury in mice. Nat Med. 1997;51:310-315. (Pubitemid 27486151)
31. Ye SF, Ichimura K, Wakame K, et al. Suppressive effects of active hexose correlated compound on the increased activity of hepatic and renal ornithine decarboxylase induced by oxidative stress. Life Sci. 2003;74:593-602. (Pubitemid 37410350)
32. Ye SF, Wakame K, Ichimura K, et al. Amelioration by active hexose correlated compound of endocrine disturbances induced by oxida-tive stress in the rat. Endocr Regul. 2004;38:7-13. (Pubitemid 39060858)
33. Wang S, Wakame K, Igarashi Y, Kosua K, Matsuzaki S. Beneficial effects of active hexose correlated compound (AHCC) on immobilization stress in the rat. Dokkyo J Med Sci. 2001;28: 559-565. (Pubitemid 33026969)
34. Vetvicka V, Vashishta A, Saraswat-Ohri S, et al. Immunological effects of yeast- and mushroom-derived beta-glucans. J Med Food. 2008;11:615-622.
35. Soltanian S, Stuyven E, Cox E, et al. Beta-glucans as immunos-timulant in vertebrates and invertebrates. Crit Rev Microbiol. 2009;35:109-138.
36. Yan J, Allendorf DJ, Brandley B. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther. 2005;5:691-702. (Pubitemid 40780552)
37. Yagita A, Maruyama S, Wakasugi S, Sukegawa Y. H-2 haplotype-dependent serum IL-12 production in tumor-bearing mice treated with various mycelial extracts. In Vivo. 2002;16:49-54. (Pubitemid 34436175)
38. H. Fujii, A. Roberts, et al. Genotoxicity and subchronic toxicity evaluation of Active Hexose Correlated Compound (AHCC). Regulatory Toxicology and Pharmacology. 2010;59:237-250.